Basilea Pharmaceutica AG
Research Basilea Pharmaceutica AG (BSLN) on Bullrun: market cap CHF 851.32M, P/E 17.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBSLN
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCHF
- Market capCHF 851.32M
- P/E17.1
- Financial periodFY2025
- RevenueCHF 232.38M
- Revenue growth11.4%
- Net incomeCHF 40.24M
- Free cash flowCHF 59.23M
- Gross margin83.1%
Valuation Snapshot
latest market cap is CHF 851.32M; P/E is 17.1.
Peer valuation comparison
Latest P/E is 17.13x versus a Healthcare sector median of 24.61x (30.4% below).
Latest P/E is 17.13x versus a Switzerland median of 19.94x (14.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CHF 232.38M | CHF 40.24M | CHF 59.23M | 83.1% | n/a | CHF 159.80M | CHF 89.22M | CHF 127.94M |
| FY2024 | CHF 208.54M | CHF 77.59M | CHF 72.57M | 81.5% | 5.83 | CHF 120.70M | CHF 111.67M | CHF 81.00M |
| FY2023 | CHF 157.63M | CHF 10.45M | CHF 13.21M | 83.0% | 0.86 | CHF 59.90M | CHF 128.61M | -CHF 10.00M |
| FY2022 | CHF 147.77M | CHF 12.15M | CHF 3.75M | 83.3% | 1.02 | CHF 84.70M | CHF 187.14M | -CHF 20.71M |
| FY2021 | n/a | n/a | n/a | n/a | -0.58 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | CHF 851.32M | 17.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CHF.
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Basilea Pharmaceutica AG's market cap?
Basilea Pharmaceutica AG's market capitalization is CHF 851.32M.
What is Basilea Pharmaceutica AG's P/E ratio?
Basilea Pharmaceutica AG's price-to-earnings (P/E) ratio is 17.1.
What does Basilea Pharmaceutica AG do?
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI).